Table 1 Patients’ characteristics (n=72)

From: Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

 

Number of patients ( n =72)

%

Sex

 Male

69

95.8

 Female

3

4.2

Age, median (range)

62 (37–72)

 

Performance status

 0–1

68

94.4

 2

4

5.6

Previous adjuvant FP chemotherapy

25

34.7

XP cycle, median (range)

4 (1–12)

 

Metastatic sites

 Lymph nodes

55

76.4

 Lung

19

26.4

 Liver

13

18.1

 Pleura

8

11.1

 Skin

5

6.9

 Bone

4

5.6

  1. Abbreviations: FP=fluouracil and cisplatin; XP=capecitabine and cisplatin.
Back to article page